ReviewMedicine2025
When therapy-induced senescence meets tumors: A double-edged sword: A review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy.Life (Basel, Switzerland) · 2026Review
- Article
- Senescent Stroma-Derived Glutamine: A Driver of Aggressiveness in Prostate and Ovarian Cancer Cells.Cells · 2026Article
- The paradox of cellular senescence in prostate cancer: from tumor suppression to tumor promotion.Frontiers in oncology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The tumor microenvironment (TME) significantly influences tumor development, progression, and clinical outcomes. Therapy-induced cellular senescence is a fundamental process affecting the microenvironment. This review summarizes the characteristics of therapy-induced cellular senescence, its beneficial and detrimental effects on the TME, and the underlying mechanisms contributing to its dual effects. It further elaborates on optimizing the beneficial aspects of therapy-induced cellular senescence while concomitantly mitigating its adverse effects in the treatment of tumors and prevention of recurrence. Finally, potential interventions, including antiaging drug therapies, senescence inducers, senescence clearance agents, and inhibition of adverse senescence-associated secretory phenotype (SASP) production were explored to inhibit the harmful SASP induced by therapy, with the aim of limiting the production of detrimental SASP in the TME, thereby reducing the risk of tumor recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.